Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Subscribe To Our Newsletter & Stay Updated